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A B S T R A C T
A 7-year old boy developed myositis secondary to intramuscular injection of benzathine penicillin-G in
the context of secondary prophylaxis for rheumatic heart disease. Side effects of intramuscular delivery
of benzathine penicillin-G are well described and include injection site pain and inflammation, but
myositis, as depicted on magnetic resonance imaging in this case, has not previously been described.
 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ idc rAn Indigenous boy from a remote Australian community had his
first episode of acute rheumatic fever (ARF) recognised at age 4 years.
He was diagnosed with rheumatic heart disease (RHD) and
commenced on 4-weekly intramuscular benzathine penicillin-G
(BPG) injections. At age 7 years, he presented with fever, left hip
monoarthritis and raised inflammatory markers (c-reactive protein
154 mg/L; erythrocyte sedimentation rate 130 mm/h; white cell
count 14.3  109 L–1; neutrophil count 10.6  109 L–1) 46 days after
his most recent BPG injection. On admission, he was administered
900 mg (2.3 ml) intramuscular BPG (Bicillin L-A) to the right gluteal
region as a scheduled dose of secondary prophylaxis. Two days later,
echocardiography and magnetic resonance imaging (MRI) of the left
hip were performed.
MRI revealed a small left hip effusion consistent with acute
arthritis, but no evidence of osteomyelitis. An unexpected finding* Corresponding author at: Department of Paediatrics, Royal Darwin Hospital,
105 Rocklands Drive, Tiwi, NT 0810, Australia. Tel.: +61 423 528 381.
E-mail address: josh.francis@nt.gov.au (J.R. Francis).
http://dx.doi.org/10.1016/j.idcr.2016.02.001
2214-2509/ 2016 The Authors. Published by Elsevier Ltd. This is an open access articl
4.0/).on MRI was extensive inflammatory change within the right
gluteus maximus, corresponding to the site of the BPG injection
(Fig. 1). Findings were consistent with myositis, likely secondary to
local inflammatory reaction to BPG.
Echocardiography demonstrated carditis with progression of
RHD (moderate mitral regurgitation, moderate aortic regurgita-
tion). Left hip pain responded promptly to oral aspirin, but the
child had significant injection-site pain and an associated limp for a
further 5 days.
Intramuscular BPG is crucial in the management and
secondary prevention of ARF and RHD. The injection is painful,
and as demonstrated in this case, can result in significant
local inflammation. These complications may be influenced by
poor injection technique or product quality, but neither of these
are likely in our setting. Poor adherence to BPG hampers the
success of RHD programmes throughout the world. Further
research into the impact of adverse effects would be informative.
Improved delivery systems for long-acting prophylactic peni-
cillin in the secondary prevention of RHD are desperately
needed.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. Coronal T2 fat saturated MRI sequences demonstrating small left hip effusion (a and b), and significant right sided soft tissue oedema affecting subcutaneous and
muscle tissue from anterior to the trochanteric region posteriorly to the sacral margin (c and d). Multiple globular low signal foci in muscle (d) represent injection site
granulomata, likely resulting from previous intramuscular injections.
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